NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan · Delayed Price · Currency is TWD 19.70
-0.40 (-1.99%)
Jan 22, 2026, 12:39 PM CST
TPEX:4732 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 180.29 | 224.32 | 160.14 | 228.59 | 249.8 | 306.92 | Upgrade | |
Revenue Growth (YoY) | -19.72% | 40.08% | -29.94% | -8.49% | -18.61% | -0.18% | Upgrade |
Cost of Revenue | 88.9 | 104.12 | 72.76 | 98.66 | 103.62 | 123.48 | Upgrade |
Gross Profit | 91.39 | 120.2 | 87.38 | 129.93 | 146.19 | 183.44 | Upgrade |
Selling, General & Admin | 57.14 | 60.17 | 53.94 | 54.06 | 49.75 | 57.39 | Upgrade |
Research & Development | 78.33 | 72.07 | 30.01 | 49.48 | 69.46 | 68.14 | Upgrade |
Operating Expenses | 135.47 | 132.22 | 83.95 | 103.58 | 119.21 | 125.51 | Upgrade |
Operating Income | -44.08 | -12.02 | 3.43 | 26.35 | 26.98 | 57.92 | Upgrade |
Interest Expense | -0.08 | -0.1 | -0.05 | -0.04 | -0.03 | -0.06 | Upgrade |
Interest & Investment Income | 7.49 | 6.64 | 5.96 | 3.61 | 1.98 | 2.34 | Upgrade |
Currency Exchange Gain (Loss) | -4.58 | 1.72 | 0.05 | -0.05 | 0.54 | -0.95 | Upgrade |
Other Non Operating Income (Expenses) | 0.02 | 0.1 | 0.1 | -0.16 | 1.25 | 0.09 | Upgrade |
EBT Excluding Unusual Items | -41.23 | -3.65 | 9.49 | 29.71 | 30.72 | 59.35 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 0.44 | 0.31 | -0.08 | -0.02 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 0 | - | - | Upgrade |
Pretax Income | -41.23 | -3.65 | 9.92 | 30.02 | 30.64 | 59.33 | Upgrade |
Income Tax Expense | 6.77 | -0.07 | -0.2 | - | -0.17 | -5.98 | Upgrade |
Earnings From Continuing Operations | -48 | -3.58 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade |
Minority Interest in Earnings | 10.99 | 4.48 | - | - | - | - | Upgrade |
Net Income | -37.01 | 0.9 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade |
Net Income to Common | -37.01 | 0.9 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade |
Net Income Growth | - | -91.14% | -66.29% | -2.54% | -52.83% | 64.54% | Upgrade |
Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 | Upgrade |
Shares Outstanding (Diluted) | 49 | 50 | 50 | 49 | 49 | 49 | Upgrade |
Shares Change (YoY) | -1.14% | -0.15% | 0.85% | 0.30% | -0.05% | 30.58% | Upgrade |
EPS (Basic) | -0.75 | 0.02 | 0.21 | 0.61 | 0.63 | 1.33 | Upgrade |
EPS (Diluted) | -0.75 | 0.02 | 0.20 | 0.61 | 0.62 | 1.32 | Upgrade |
EPS Growth | - | -90.90% | -67.17% | -1.75% | -53.03% | 26.05% | Upgrade |
Free Cash Flow | -22.58 | -2.91 | 61.9 | 13.85 | 33.72 | 54.61 | Upgrade |
Free Cash Flow Per Share | -0.46 | -0.06 | 1.24 | 0.28 | 0.68 | 1.11 | Upgrade |
Dividend Per Share | - | - | 0.200 | 0.500 | 0.300 | 0.094 | Upgrade |
Dividend Growth | - | - | -60.00% | 66.67% | 218.13% | - | Upgrade |
Gross Margin | 50.69% | 53.58% | 54.56% | 56.84% | 58.52% | 59.77% | Upgrade |
Operating Margin | -24.45% | -5.36% | 2.14% | 11.53% | 10.80% | 18.87% | Upgrade |
Profit Margin | -20.53% | 0.40% | 6.32% | 13.13% | 12.33% | 21.28% | Upgrade |
Free Cash Flow Margin | -12.53% | -1.30% | 38.65% | 6.06% | 13.50% | 17.79% | Upgrade |
EBITDA | -37.61 | -5.57 | 9.84 | 37.15 | 38.01 | 65.54 | Upgrade |
EBITDA Margin | -20.86% | -2.48% | 6.14% | 16.25% | 15.22% | 21.35% | Upgrade |
D&A For EBITDA | 6.47 | 6.45 | 6.4 | 10.8 | 11.03 | 7.62 | Upgrade |
EBIT | -44.08 | -12.02 | 3.43 | 26.35 | 26.98 | 57.92 | Upgrade |
EBIT Margin | -24.45% | -5.36% | 2.14% | 11.53% | 10.80% | 18.87% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.